Abstract 346P
Background
ET is the mainstay treatment (tx) for HR+ eBC but they have persistent side effects that negatively affect QoL, leading to early tx discontinuation and compromising outcomes. We describe the incidence of ET toxicity and its QoL impact in CANTO.
Methods
CANTO (NCT01993498) is a prospective, longitudinal cohort study enrolling pts with invasive (cT0-cT3, cN0-3, no metastases) BC from 26 French cancer centres. Pts with HR+, HER2– eBC treated with adj ET were followed for the first 3 years (yrs) after eBC diagnosis. Pt demographics, clinical data, adherence, symptoms and QoL were collected. Questionnaires were administered at baseline (BL), 3–6 months (mo; M0) after primary surgery, chemotherapy or radiotherapy completion (whichever came last), and 12 mo, 36 mo and 60 mo after M0. Descriptive analyses were conducted for frequency of symptoms and mean/median QoL questionnaires summary scores.
Results
Of the 5564 pts who met the inclusion criteria (median age: 57 yrs), 63% were post-menopausal and 52% had stage I eBC at diagnosis. The table shows QoL and toxicity data. Global and functioning QoL remained high at BL and during tx. BC-specific symptoms persisted during tx. Pain was the most prevalent toxicity in the first 3 yrs; prevalence of muscular and joint pain increased over time. Mean intensity of global, muscular and joint pain all remained high over the course of ET (median intensity: ∼6 [0–10 scale]). ET adherence was 81–93% over time; in the first 3 yrs, 23% switched ET and 7% discontinued adj ET; toxicity was the main reason cited. Table: 346P
BL | M0 | 12 mo | 36 mo | |
Mean EORTC QLQ-C30 | 83 | 80 | 79 | 80 |
Global health status | 68 | 68 | 66 | 66 |
Physical functioning | 91 | 85 | 84 | 85 |
Role functioning | 87 | 80 | 82 | 83 |
Emotional functioning | 65 | 72 | 70 | 71 |
Cognitive functioning | 82 | 79 | 77 | 78 |
Social functioning | 91 | 83 | 85 | 86 |
Insomnia | 43 | 41 | 43 | 42 |
Fatigue | 28 | 36 | 35 | 34 |
Pain | 15 | 28 | 30 | 29 |
Mean EORTC QLQ-BR23 | ||||
Body image | 88 | 75 | 77 | 79 |
Future perspective | 49 | 56 | 61 | 64 |
Sexual functioning | 26 | 26 | 26 | 24 |
Breast symptoms | 13 | 26 | 20 | 16 |
Systemic therapy side effects | 11 | 20 | 19 | 18 |
Arm symptoms | 9 | 21 | 19 | 17 |
Toxicity, % | ||||
Global and back pain | - | 71 | 74 | 72 |
Muscular and back | - | 32 | 36 | 38 |
Joint and back | - | 59 | 68 | 70 |
Conclusions
While global and functional QoL remained high in the first 3 yrs after eBC diagnosis, BC-specific symptoms slightly increased/persisted during ET. This study confirmed long-term toxicity of ET, particularly pain. Better management of symptoms and supportive interventional strategies are needed to further improve QoL in eBC.
Clinical trial identification
NCT01993498, first posted November 25, 2013.
Editorial acknowledgement
Research support for third-party writing assistance for this abstract, furnished by Eleanor Porteous, MSc, of Health Interactions, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Legal entity responsible for the study
F. Hoffmann-La Roche Ltd.
Funding
F. Hoffmann-La Roche Ltd.
Disclosure
A. Bertaut: Non-Financial Interests, Personal, Other, Research funding: Support for third-party writing assistance from F. Hoffmann-La Roche Ltd: F. Hoffmann-La Roche Ltd. T. Badovinac Crnjevic: Financial Interests, Personal, Full or part-time Employment: F. Hoffmann-La Roche Ltd/ Genentech; Financial Interests, Personal, Stocks/Shares: F. Hoffmann-La Roche Ltd; Non-Financial Interests, Personal, Other, Research funding: Support for third-party writing assistance from F. Hoffmann-La Roche Ltd: F. Hoffmann-La Roche Ltd. A. Martin, C. Gaudin: Non-Financial Interests, Personal, Other, Research funding: Support for third-party writing assistance: F. Hoffmann-La Roche Ltd. L. Chen: Financial Interests, Personal, Full or part-time Employment: Genentech, Inc.; Financial Interests, Personal, Stocks/Shares: F. Hoffmann-La Roche Ltd; Non-Financial Interests, Personal, Other, Research funding: Support for third-party writing assistance: F. Hoffmann-La Roche Ltd.
Resources from the same session
371P - Adherence to standardized and structured electronic symptom reporting (ePRO) via mobile app in HER2-positive breast cancer treated with HER2 biosimilar trastuzumab
Presenter: Andreas Trojan
Session: Poster session 03
372P - Prevalence of BRCA1 and BRCA2 mutation among Indian breast cancer patients: A multicentre cross-sectional study
Presenter: Shona Nag
Session: Poster session 03
374P - Evaluation of symptom severity, tolerability, and physical function in the I-SPY2 trial
Presenter: Amrita Basu
Session: Poster session 03
375TiP - A phase I, 2-part, multicenter, first-in-human dose-escalation and dose-expansion study of DS-1103a with trastuzumab deruxtecan (T-DXd) in patients with advanced solid tumors
Presenter: Ludimila Cavalcante
Session: Poster session 03
388P - Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC)
Presenter: Junji Tsurutani
Session: Poster session 03
391P - Detrimental effect on overall survival of CDK4/6 inhibitor dose reduction if immortal time bias is considered
Presenter: Andreas Bjerrum
Session: Poster session 03
392P - The prognostic impact of BMI in patients with HR+/HER2- advanced breast cancer on first-line endocrine therapy with or without a CDK 4/6 inhibitor
Presenter: Senna Lammers
Session: Poster session 03